Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-06-20T11:39:39.189Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of cariprazine as an impulsivity regulator in an adolescent with non suicidal self-injury and suicidal attempts. Case report

Published online by Cambridge University Press:  19 July 2023

P. Del Sol Calderon ,
A. Izquierdo de la Puente ,
R. Fernández Fernández  and
M. García Moreno
P. Del Sol Calderon*
Affiliation:
Psychiatry, Hospital Puerta de Hierro, Majadahonda
A. Izquierdo de la Puente
Affiliation:
Psychiatry, Hospital Puerta de Hierro, Majadahonda
R. Fernández Fernández
Affiliation:
Psychiatry, Hospital Infanta Cristina, Madrid, Spain
M. García Moreno
Affiliation:
Psychiatry, Hospital Puerta de Hierro, Majadahonda
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Adolescents with emotional dysregulation are at risk for self-injury. Antipsychotics are often used to manage these symptoms.

Objectives

The aim of the present case is to show the use of cariprazine as an effective drug for emotional dysregulation and impulsivity in a 17-year-old adolescent girl

Methods

Case report

Results

The patient was a 17-year-old female admitted to in patient psychiatric unit for a self-harm attempt due to sertraline overdose. She was being followed up for self-injury, anxiety and eating disorder symptoms. Her treatment was sertraline 200 mg, diazepam 20 mg per day and olanzapine 15 mg per day. With this medication she had gained up to 7 kgs in 4 months. A progressive change was made with cariprazine up to 3 mg and olanzapine was reduced to 2.5 mg at night. With this adjustment the patient did not present worsening in anxiety levels, with adequate impulse control and being able to perform emotional regulation strategies.

Conclusions

Although it has no indication in patients under 18 years of age, it shows a case of good tolerance and efficacy for the management of impulsivity by improving emotional regulation. Cariprazine is an atypical antipsychotic that works through partial agonism on dopaminergic receptors, serotonin 5-HT1A receptors and an antagonist at the 5-HT2B receptors, with moderate affinity for adrenergic, histaminergic, and cholinergic receptors reducing the likelihood of side effects

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S739
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.